The number of new medicines launched in Europe has fallen by 35%.

Omissions

• The claim omits the specific time period: the 35% decline refers to the 10 months since the US Most Favored Nation (MFN) executive order of May 2025, compared to the preceding 10 months — a short-term comparison, not a long-term structural trend.
• The claim does not cite the source: the figure comes from a proprietary GlobalData Price Intelligence (POLI) analysis, a commercial market research firm, not from an official European agency such as the EMA or Eurostat.
• The phrase 'and this is just the beginning' is a political prediction and not a verifiable factual claim.
• The MEP could not have known all sources: the Reuters article (2026-03-31) and the Pharmaceutical Technology analysis were published before the session date (2026-05-18), making them contemporaneously available, but the GlobalData primary report is not publicly accessible for independent verification.
• No primary official source (EMA, Eurostat, European Commission) was found that independently corroborates the 35% figure; all sources rely on the same single GlobalData analysis.

Sources

• SecondaryReutersDrug launches in EU markets fell by some 35% in the 10 months since Trump's executive order, compared with the previous 10 months, a GlobalData analysis found.
• SecondaryPharmaceutical TechnologyGlobalData's Price Intelligence (POLI) analysis indicates a noticeable drop in the number of pharmaceutical launches across Europe, with analysis showing that new medicine launches fell by roughly 35% in the 10 months since the US MFN executive order compared to the prior 10 months.
• SecondaryReutersSince the policy was launched in May last year, new drug launches in Europe have fallen by around a third, a GlobalData analysis found.